We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

142 hedge funds and large institutions have $1.21B invested in Aimmune Therapeutics in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 48 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

342% more call options, than puts

Call options by funds: $14.9M | Put options by funds: $3.37M

3% less capital invested

Capital invested by funds: $1.25B → $1.21B (-$34.6M)

6% less funds holding

Funds holding: 151 → 142 (-9)

17% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 48

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

31% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 29

Holders
142
Holders Change
-9
Holders Change %
-5.96%
% of All Funds
3.25%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
20
Increased
40
Reduced
48
Closed
29
Calls
$14.9M
Puts
$3.37M
Net Calls
+$11.5M
Net Calls Change
+$8.52M

Top Buyers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
+$11.1M
2
BlackRock
BlackRock
New York
+$9.58M
3
Bank of America
Bank of America
North Carolina
+$6.31M
4
GKIM
GW&K Investment Management
Massachusetts
+$5.27M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.82M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$37M
2
State Street
State Street
Massachusetts
-$16.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.7M
4
AC
Aisling Capital
New York
-$7.07M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jennison Associates
26
Jennison Associates
New York
$11.8M +$97.4K +3,442 +0.8%
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$11M +$1.08M +38,227 +10%
Point72 Asset Management
28
Point72 Asset Management
Connecticut
$10.4M -$37M -1,306,403 -77%
Deutsche Bank
29
Deutsche Bank
Germany
$9.57M +$1.43M +50,442 +17%
Massachusetts Financial Services
30
Massachusetts Financial Services
Massachusetts
$8.84M +$1.8M +63,546 +24%
HCMT
31
Highland Capital Management (Texas)
Texas
$8.03M +$152K +5,360 +2%
Goldman Sachs
32
Goldman Sachs
New York
$7.11M +$1.18M +41,716 +19%
Norges Bank
33
Norges Bank
Norway
$6.88M – – –
SI
34
Sofinnova Investments
California
$6.06M -$4.32M -152,749 -41%
Charles Schwab
35
Charles Schwab
California
$5.88M +$235K +8,322 +4%
SIM
36
Spark Investment Management
New York
$5.7M -$659K -23,300 -10%
CWG
37
C WorldWide Group
Denmark
$5.68M -$1.09M -38,567 -16%
ERSOT
38
Employees Retirement System of Texas
Texas
$5.31M – – –
PVAM
39
Pacific View Asset Management
California
$5.18M -$135K -4,771 -2%
GKIM
40
GW&K Investment Management
Massachusetts
$5.08M +$5.27M +186,193 New
Bank of New York Mellon
41
Bank of New York Mellon
New York
$4.67M -$20.2K -714 -0.4%
Hudson Bay Capital Management
42
Hudson Bay Capital Management
Connecticut
$4.09M – – –
JP Morgan Chase
43
JP Morgan Chase
New York
$3.98M +$263K +9,289 +7%
American Century Companies
44
American Century Companies
Missouri
$3.97M +$694K +24,531 +20%
Millennium Management
45
Millennium Management
New York
$2.88M -$313K -11,075 -9%
AA
46
ALPS Advisors
Colorado
$2.82M +$549K +19,414 +23%
TA
47
Teachers Advisors
New York
$2.81M +$587K +20,751 +25%
TD Asset Management
48
TD Asset Management
Ontario, Canada
$2.67M +$257K +9,100 +10%
TCIM
49
TIAA CREF Investment Management
New York
$2.3M -$199K -7,033 -8%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$2.12M +$1.69M +59,901 +335%
1
2
3 4 5

AIMT Hedge Fund Activity: Q3 2018 in Review

142 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2018, worth a combined $1.21B — down 2.8% from $1.25B a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of AIMT and 20 opened new positions — a net loss of 9 holders — while 48 trimmed existing stakes and 40 added.

The largest buyer was AllianceBernstein, adding an estimated $11.1M. The largest seller was Point72 Asset Management, cutting an estimated $37M.

  • 142 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2018, down from 151 in Q2 2018.
  • Funds reported $1.21B of Aimmune Therapeutics stock for Q3 2018, down 2.8% quarter-over-quarter.
  • 20 funds opened new Aimmune Therapeutics positions in Q3 2018 and 29 closed out, a net change of -9 holders.
  • The largest Aimmune Therapeutics buyer in Q3 2018 was AllianceBernstein, an estimated $11.1M added.
  • The largest Aimmune Therapeutics seller in Q3 2018 was Point72 Asset Management, an estimated $37M sold.

Based on aggregated 13F filings for Q3 2018.